Therapeutic potential of allicin-rich garlic preparations: Emphasis on clinical evidence toward upcoming drugs formulation

  • Javad Sharifi-Rad
  • , Nathália Cristina Cirone Silva
  • , Arvind Jantwal
  • , Indra D. Bhatt
  • , Farukh Sharopov
  • , William C. Cho
  • , Yasaman Taheri
  • , Natália Martins

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

24 Citas (Scopus)

Resumen

Garlic has been used for a long time in human history. Allicin, the main active compound present in freshly injured garlic, is enzymatically formed from alliin. Allicin has shown doubtless beneficial effects and even be conceived as medicine. The present review highlights allicin-associated studies. Indeed, clinical studies on healthy subjects have evidenced that standardized garlic treatment (900 mg/day) significantly reduces total cholesterol (TC) and low-density lipoprotein cholesterol (c-LDL). Besides, allicin also led to a marked improvement in mouth opening, burning sensation, and oral health-related quality of life on stage II oral submucous fibrosis patients. Interestingly, in children, allicin also has been proposed for thrush prevention and as an alternative antibiotic therapy. Nonetheless, there is particular attention to allicin bioavailability, given its high instability. Although clinical evidence has promoted allicin release from garlic powder tablets under simulated gastrointestinal conditions, garlic tablets are those that have provided less alliinase protection due to its fast disintegration, releasing low allicin amounts.

Idioma originalInglés
Número de artículo5555
PublicaciónApplied Sciences (Switzerland)
Volumen9
N.º24
DOI
EstadoPublicada - 1 dic. 2019
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'Therapeutic potential of allicin-rich garlic preparations: Emphasis on clinical evidence toward upcoming drugs formulation'. En conjunto forman una huella única.

Citar esto